"We were thrilled with the meeting and the attendance," ACC President Cathie Biga, RN, told Cardiovascular Business.

The PREVENT study, presented at ACC.24, examined more than 1,600 patients with high-risk plaques treated with either preventive PCI or medical therapy alone. Outcomes were much better for the PCI group after two years, but the findings may lead to more questions than answers. 

TAVR is noninferior to SAVR when treating low-risk patients, according to new data presented at ACC.24. In fact, it is associated with multiple benefits over surgery.

“This is the first time in a very long time that we have a positive study for managing cardiogenic shock,” one cardiologist said. 

The SMART trial included one-year data from TAVR patients randomized to receive either a self-expanding Evolut valve or a balloon-expandable Sapien 3 valve. All patients presented with symptomatic severe aortic stenosis and a small aortic annulus. A whopping 87% of participants were women. 

The new research, based on data from more than 600 patients, was presented at ACC.24 in Atlanta and published in the New England Journal of Medicine. Semaglutide is sold by Novo Nordisk under the brand name Wegovy.

ACC.24 in Atlanta began Saturday, April 6, with a series of late-breaking clinical trials exploring brand new treatment strategies. 

Transcatheter pulmonary valve replacement is still linked to certain risks, researchers noted, but new data confirm it is a safe, effective treatment option for patients with severe PR.